Lung cancer is a leading cause of cancer-related death worldwide, and treatment options are limited for patients with advanced disease. However, a recent study published in the journal Nature has shown promising results for a new approach to treating lung cancer using personalized medicine.

The researchers analyzed the genomes of more than 2,000 patients with non-small cell lung cancer and identified several genetic mutations that were associated with a better response to immunotherapy, a type of cancer treatment that helps the immune system fight cancer.

The researchers also developed a personalized treatment algorithm that took into account the genetic mutations of each patient's tumor. They found that patients who received personalized treatment based on their tumor's genetic profile had a better response to immunotherapy than those who received standard treatment.

The lead author of the study, Dr. Trever Bivona, said that the results were "very promising" and showed that personalized medicine could be a viable option for treating lung cancer.

"This study demonstrates that personalized medicine can improve outcomes for patients with lung cancer and provides a roadmap for developing personalized treatments for other types of cancer," Dr. Bivona said.

Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352312/